|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||1.40 / 6.30|
Thin trading is impeding momentum, but here are 4 stocks on my radar.
Will pension funds sell stocks after their run higher in order to maintain the same allocation levels to bonds and equities?
Markets look set to continue their election rally as violence casts a pall over Europe.
Conatus Pharmaceuticals (CNAT) stock was boosted on Tuesday after Allergan (AGN) agreed to buy Tobira Therapeutics (TBRA) at a 500% premium.
Conatus Pharmaceuticals' (CNAT) patented liver drug emricasan has been identified as a promising treatment for the Zika virus.
Company's non-invasive BreathID® System to be used to quantitate liver function in Conatus Phase IIb clinical trial of emricasan; Currently no approved non-invasive diagnostic tests exist to diagnose or monitor NASH which affects 2-5% of the US population
Conference Call and Webcast Presentation at 8:00 a.m. ET Today
Late Breaker Oral Presentation Tomorrow to Detail Phase 2 Liver Cirrhosis Trial 3-month Results